316 related articles for article (PubMed ID: 8306342)
1. Two molecular pathways to transitional cell carcinoma of the bladder.
Spruck CH; Ohneseit PF; Gonzalez-Zulueta M; Esrig D; Miyao N; Tsai YC; Lerner SP; Schmütte C; Yang AS; Cote R
Cancer Res; 1994 Feb; 54(3):784-8. PubMed ID: 8306342
[TBL] [Abstract][Full Text] [Related]
2. Role of chromosome 9 in human bladder cancer.
Miyao N; Tsai YC; Lerner SP; Olumi AF; Spruck CH; Gonzalez-Zulueta M; Nichols PW; Skinner DG; Jones PA
Cancer Res; 1993 Sep; 53(17):4066-70. PubMed ID: 8358736
[TBL] [Abstract][Full Text] [Related]
3. Evidence for two tumor suppressor loci associated with proximal chromosome 9p to q and distal chromosome 9q in bladder cancer and the initial screening for GAS1 and PTC mutations.
Simoneau AR; Spruck CH; Gonzalez-Zulueta M; Gonzalgo ML; Chan MF; Tsai YC; Dean M; Steven K; Horn T; Jones PA
Cancer Res; 1996 Nov; 56(21):5039-43. PubMed ID: 8895761
[TBL] [Abstract][Full Text] [Related]
4. Occurrence of chromosome 9 and p53 alterations in multifocal dysplasia and carcinoma in situ of human urinary bladder.
Hartmann A; Schlake G; Zaak D; Hungerhuber E; Hofstetter A; Hofstaedter F; Knuechel R
Cancer Res; 2002 Feb; 62(3):809-18. PubMed ID: 11830537
[TBL] [Abstract][Full Text] [Related]
5. Urothelium-specific expression of an oncogene in transgenic mice induced the formation of carcinoma in situ and invasive transitional cell carcinoma.
Zhang ZT; Pak J; Shapiro E; Sun TT; Wu XR
Cancer Res; 1999 Jul; 59(14):3512-7. PubMed ID: 10416618
[TBL] [Abstract][Full Text] [Related]
6. Molecular alterations associated with bladder cancer initiation and progression.
Cordon-Cardo C
Scand J Urol Nephrol Suppl; 2008 Sep; (218):154-65. PubMed ID: 18815930
[TBL] [Abstract][Full Text] [Related]
7. Partial allelotype of carcinoma in situ of the human bladder.
Rosin MP; Cairns P; Epstein JI; Schoenberg MP; Sidransky D
Cancer Res; 1995 Nov; 55(22):5213-6. PubMed ID: 7585577
[TBL] [Abstract][Full Text] [Related]
8. p53 mutations and prognosis in bladder tumors.
Uchida T; Wada C; Ishida H; Wang C; Egawa S; Yokoyama E; Kameya T; Koshiba K
J Urol; 1995 Apr; 153(4):1097-104. PubMed ID: 7869472
[TBL] [Abstract][Full Text] [Related]
9. Frequent association of p53 gene mutation in invasive bladder cancer.
Fujimoto K; Yamada Y; Okajima E; Kakizoe T; Sasaki H; Sugimura T; Terada M
Cancer Res; 1992 Mar; 52(6):1393-8. PubMed ID: 1540947
[TBL] [Abstract][Full Text] [Related]
10. Allelic loss of chromosome 17p distinguishes high grade from low grade transitional cell carcinomas of the bladder.
Olumi AF; Tsai YC; Nichols PW; Skinner DG; Cain DR; Bender LI; Jones PA
Cancer Res; 1990 Nov; 50(21):7081-3. PubMed ID: 2208176
[TBL] [Abstract][Full Text] [Related]
11. Allelic loss of p53 gene is associated with genesis and maintenance, but not invasion, of mouse carcinoma in situ of the bladder.
Cheng J; Huang H; Pak J; Shapiro E; Sun TT; Cordon-Cardo C; Waldman FM; Wu XR
Cancer Res; 2003 Jan; 63(1):179-85. PubMed ID: 12517796
[TBL] [Abstract][Full Text] [Related]
12. Gene expression in the urinary bladder: a common carcinoma in situ gene expression signature exists disregarding histopathological classification.
Dyrskjøt L; Kruhøffer M; Thykjaer T; Marcussen N; Jensen JL; Møller K; Ørntoft TF
Cancer Res; 2004 Jun; 64(11):4040-8. PubMed ID: 15173019
[TBL] [Abstract][Full Text] [Related]
13. The p53 tumor suppressor gene and nuclear protein: basic science review and relevance in the management of bladder cancer.
Smith ND; Rubenstein JN; Eggener SE; Kozlowski JM
J Urol; 2003 Apr; 169(4):1219-28. PubMed ID: 12629332
[TBL] [Abstract][Full Text] [Related]
14. Superimposed histologic and genetic mapping of chromosome 17 alterations in human urinary bladder neoplasia.
Chaturvedi V; Li L; Hodges S; Johnston D; Ro JY; Logothetis C; von Eschenbach AC; Batsakis JG; Czerniak B
Oncogene; 1997 May; 14(17):2059-70. PubMed ID: 9160886
[TBL] [Abstract][Full Text] [Related]
15. [Molecular changes in development and progression of urothelial carcinoma].
Hartmann A
Verh Dtsch Ges Pathol; 2003; 87():172-84. PubMed ID: 16888910
[TBL] [Abstract][Full Text] [Related]
16. TP53 alterations as a potential diagnostic marker in superficial bladder carcinoma and in patients serum, plasma and urine samples.
Dahse R; Utting M; Werner W; Schimmel B; Claussen U; Junker K
Int J Oncol; 2002 Jan; 20(1):107-15. PubMed ID: 11743649
[TBL] [Abstract][Full Text] [Related]
17. Mutation spectrum of the 9q34 tuberous sclerosis gene TSC1 in transitional cell carcinoma of the bladder.
Knowles MA; Habuchi T; Kennedy W; Cuthbert-Heavens D
Cancer Res; 2003 Nov; 63(22):7652-6. PubMed ID: 14633685
[TBL] [Abstract][Full Text] [Related]
18. Bladder cancer.
Ozen H
Curr Opin Oncol; 1998 May; 10(3):273-8. PubMed ID: 9619365
[TBL] [Abstract][Full Text] [Related]
19. High frequency of chromosome 9p allelic loss and CDKN2 tumor suppressor gene alterations in squamous cell carcinoma of the bladder.
Gonzalez-Zulueta M; Shibata A; Ohneseit PF; Spruck CH; Busch C; Shamaa M; El-Baz M; Nichols PW; Gonzalgo ML; Elbaz M [corrected to El-Baz M]
J Natl Cancer Inst; 1995 Sep; 87(18):1383-93. PubMed ID: 7658499
[TBL] [Abstract][Full Text] [Related]
20. Role of activating fibroblast growth factor receptor 3 mutations in the development of bladder tumors.
Zieger K; Dyrskjøt L; Wiuf C; Jensen JL; Andersen CL; Jensen KM; Ørntoft TF
Clin Cancer Res; 2005 Nov; 11(21):7709-19. PubMed ID: 16278391
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
